Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1025)	7/16/1998 11:13:00 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1491

Of the 29% royalty, after cost-of-product and payments to the inventor are made, Pharmos ends up with 20%: BUT this is after the $5 million advance payment by B&L is paid off. Until it is, B&L holds back 39% of the monies due to Pharmos, as a payment towards the $5million. Roughly, this means Pharmos nets 8.8% ((29%*.61)-9%) on sales until the advance is paid off. This would change again depending on the deal that is worked out with the Alrex marketing partner, since reportedly B&L wants Pharmos to absorb some of the cost of the partner's share. NeuroInvestment (www.neuroinv.com)